ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 368

Detrimental Impact Of Long-Term Cumulative Burden Of Rheumatoid Arthritis (RA) Disease Severity On Cardiovascular Outcomes In RA

Elena Myasoedova1, Birkan Ilhan2, Helen Khun3, Eric L. Matteson4 and Cynthia S. Crowson3, 1Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, 2Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey, 3Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 4Rheumatology, Mayo Clinic, Rochester, MN

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Comorbidities in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Several studies have shown the associations of various measures of rheumatoid arthritis (RA) disease severity with unfavorable cardiovascular (CV) outcomes in RA. The association of cumulative RA severity burden on CV disease has not been investigated in longitudinal population-based studies. We aimed to examine the impact of long-term cumulative burden of RA disease severity on CV outcomes in RA.

Methods: A previously validated Claims-based Index of RA Severity (CIRAS; Ting et al. Arth Res Ther. 2008;10:R95) was used to estimate RA severity in a population-based incident cohort of patients with RA who were >/= 30 years old, fulfilled 1987 ACR criteria between 1/1/1988 and 1/1/2008, and had no history of CV disease. Claims-based data were used to calculate the CIRAS score: number of inflammatory marker tests, platelet counts, and chemistry panels; number of rheumatology visits, rehabilitation visits, assessment of rheumatoid factor, and the presence of Felty’s syndrome. CIRAS score was calculated at RA incidence and monthly during the follow-up using 12 months of prior information for each estimate. Data on antirheumatic medications (i.e. methotrexate, hydroxychloroquine, other disease-modifying antirheumatic drugs, biologics and corticosteroids), CV risk factors (i.e. hypertension, diabetes, smoking and dyslipidemia), incident CV events (myocardial infarction, CV death, angina, stroke, intermittent claudication, and heart failure) were collected from the medical records. Cox models with time-dependent covariates were used to assess the association of CIRAS score with the risk of CV events, adjusting for age, sex, calendar year of RA, CV risk factors and antirheumatic medication use.

Results: The study included 526 patients with RA (mean age at RA incidence 54.6 years, 71% female). The mean CIRAS score at RA incidence was 4.5 (standard deviation [SD] 1.9; min 0.6; max 9.5). During the mean follow-up of 7.3 years 103 CV events occurred. There was no apparent association of baseline CIRAS with the occurrence of CV events (hazard ratio [HR] 1.08 per 1 unit increase, 95% confidence interval [CI] 0.96, 1.22, p=0.20). The associations of the highest CIRAS value in the first year (HR 1.14 per 1 unit increase, 95%CI 0.99, 1.31, p=0.063) and monthly CIRAS (HR 1.13 per 1 unit increase, 95%CI 0.98, 1.31, p=0.096) with CV events approached statistical significance. Increase in cumulative moving average of monthly CIRAS was associated with significantly increased risk of CV events (HR 1.34 per 1 unit increase, 95%CI 1.09, 1.66). By cumulative moving percentage of time, patients who spent more time in medium  and high CIRAS tertiles were more likely to have an increased risk of CV events vs those who spent more time in the lower tertile (HR 1.07, 95%CI 0.97, 1.17 and HR 1.14, 95%CI 1.03, 1.25, respectively, per 10 unit increase in the amount of time in the tertile). 

Conclusion: Higher long-term burden of RA severity as expressed by cumulative moving average of monthly CIRAS and cumulative moving percentage of time in medium and high CIRAS tertiles was associated with significantly increased risk of CV events in RA suggesting accrued detrimental impact of RA severity over time.


Disclosure:

E. Myasoedova,

Genentech, Inc.,

2;

B. Ilhan,
None;

H. Khun,

Genentech, Inc.,

2;

E. L. Matteson,

Genentech, Inc.,

2;

C. S. Crowson,

Genentech, Inc.,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/detrimental-impact-of-long-term-cumulative-burden-of-rheumatoid-arthritis-ra-disease-severity-on-cardiovascular-outcomes-in-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology